Literature DB >> 19641941

Transient secondary hyperparathyroidism following intravenous infusion of zoledronic acid.

Stergios A Polyzos, Athanasios D Anastasilakis, Evangelos Terpos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19641941     DOI： 10.1007/s00520-009-0704-5

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


× No keyword cloud information.
  9 in total

1.  Hyperparathyroidism secondary to zoledronic acid infusion: case report.

Authors:  Meral Sayin; Gozde Yazici
Journal:  Support Care Cancer       Date:  2009-02-10       Impact factor: 3.603

Review 2.  Bisphosphonates--role in cancer therapies.

Authors:  Bhoomi Mehrotra
Journal:  J Oral Maxillofac Surg       Date:  2009-05       Impact factor: 1.895

Review 3.  Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas.

Authors:  J F Seymour; R F Gagel
Journal:  Blood       Date:  1993-09-01       Impact factor: 22.113

4.  Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor kappaB ligand on adult T-cell leukemia cells.

Authors:  Kisato Nosaka; Takeshi Miyamoto; Tatsunori Sakai; Hiroaki Mitsuya; Toshio Suda; Masao Matsuoka
Journal:  Blood       Date:  2002-01-15       Impact factor: 22.113

5.  Severe hypocalcemia following bisphosphonate treatment in a patient with Paget's disease of bone.

Authors:  Heather E Whitson; Bruce Lobaugh; Kenneth W Lyles
Journal:  Bone       Date:  2006-06-12       Impact factor: 4.398

6.  Relationships between pharmacokinetics and rate of bone turnover after intravenous bisphosphonate (olpadronate) in patients with Paget's disease of bone.

Authors:  Serge C L M Cremers; Marelise E M W Eekhoff; Jan Den Hartigh; Neveen A T Hamdy; Pieter Vermeij; Socrates E Papapoulos
Journal:  J Bone Miner Res       Date:  2003-05       Impact factor: 6.741

Review 7.  Dickkopf-1: a suitable target for the management of myeloma bone disease.

Authors:  Maria Gavriatopoulou; Meletios-Athanasios Dimopoulos; Dimitrios Christoulas; Magdalini Migkou; Marina Iakovaki; Maria Gkotzamanidou; Evangelos Terpos
Journal:  Expert Opin Ther Targets       Date:  2009-07       Impact factor: 6.902

8.  The effect of zoledronic acid on serum dickkopf-1, osteoprotegerin, and RANKL in patients with Paget's disease of bone.

Authors:  S A Polyzos; A D Anastasilakis; Z Efstathiadou; M Kita; I Litsas; A Avramidis; G Arsos; E Moralidis; S Gerou; V Pavlidou; A Papatheodorou; E Terpos
Journal:  Horm Metab Res       Date:  2009-08-10       Impact factor: 2.936

9.  Scintigraphic, biochemical, and clinical response to zoledronic acid treatment in patients with Paget's disease of bone.

Authors:  Avraam Avramidis; Stergios A Polyzos; Efstratios Moralidis; Georgios Arsos; Zoe Efstathiadou; Konstantinos Karakatsanis; Georgios Grollios; Marina Kita
Journal:  J Bone Miner Metab       Date:  2008-11-01       Impact factor: 2.626
  9 in total
  7 in total

1.  Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget's disease.

Authors:  Stergios A Polyzos; Athanasios D Anastasilakis; Ioannis Litsas; Zoe Efstathiadou; Marina Kita; Georgios Arsos; Efstratios Moralidis; Athanasios Papatheodorou; Evangelos Terpos
Journal:  J Bone Miner Metab       Date:  2010-06-09       Impact factor: 2.626

2.  Denosumab versus zoledronic acid in patients previously treated with zoledronic acid.

Authors:  A D Anastasilakis; S A Polyzos; A Gkiomisi; Z G Saridakis; D Digkas; I Bisbinas; G T Sakellariou; A Papatheodorou; P Kokkoris; P Makras
Journal:  Osteoporos Int       Date:  2015-05-20       Impact factor: 4.507

3.  Hypocalcemia following Neridronate Administration in Pediatric Patients with Osteogenesis Imperfecta: A Prospective Observational Study.

Authors:  Evelina Maines; Elisa Tadiotto; Grazia Morandi; Michela Fedrizzi; Rossella Gaudino; Paolo Cavarzere; Alessandra Guzzo; Franco Antoniazzi
Journal:  J Pediatr Genet       Date:  2020-01-06

4.  Differential Effects of Teriparatide and Denosumab on Intact PTH and Bone Formation Indices: AVA Osteoporosis Study.

Authors:  David W Dempster; Hua Zhou; Robert R Recker; Jacques P Brown; Christopher P Recknor; E Michael Lewiecki; Paul D Miller; Sudhaker D Rao; David L Kendler; Robert Lindsay; John H Krege; Jahangir Alam; Kathleen A Taylor; Boris Janos; Valerie A Ruff
Journal:  J Clin Endocrinol Metab       Date:  2016-02-09       Impact factor: 5.958

5.  Zoledronic acid-induced transient hepatotoxicity in a patient effectively treated for Paget's disease of bone.

Authors:  S A Polyzos; J Kountouras; A D Anastasilakis; I Litsas; M Kita; G Arsos; E Moralidis; E Terpos
Journal:  Osteoporos Int       Date:  2010-04-21       Impact factor: 4.507

6.  Early clinical effects, safety, and predictors of the effects of romosozumab treatment in osteoporosis patients: one-year study.

Authors:  A Tominaga; K Wada; K Okazaki; H Nishi; Y Terayama; Y Kato
Journal:  Osteoporos Int       Date:  2021-03-26       Impact factor: 4.507

7.  Serum homocysteine, folate and vitamin B12 in patients with Paget's disease of bone: the effect of zoledronic acid.

Authors:  Stergios A Polyzos; Athanasios D Anastasilakis; Zoe Efstathiadou; Ioannis Litsas; Marina Kita; Athanasios Panagiotou; Athanasios Papatheodorou; Georgios Arsos; Efstratios Moralidis; Georgios Barmpalios; Efthimia Zafeiriadou; Efthimia Triantafillidou; Eleni Makrigiannaki; Evangelos Terpos
Journal:  J Bone Miner Metab       Date:  2009-10-21       Impact factor: 2.626
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.